CD3+ (p = 0.010), CD4+ (p = 0.045), and CD8+ (p = 0.033) TILs in the central tumor area and CD8+ TILs in the invasive margin area (p = 0.004) showed significant higher levels in LVI(+) than in LVI(−) patients. This evidence concerns the gene CD4 and neoplasm.